TD Cowen raised the firm’s price target on Ultragenyx (RARE) to $73 from $61 and keeps a Buy rating on the shares. The firm updated its model and corresponding estimates in conjunction with its Q3 earnings preview.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Ultragenyx price target raised to $83 from $73 at BofA
- Inozyme appoints Erik Harris to board of directors
- Ultragenyx receives Breakthrough Therapy Designation for setrusumab
- Ultragenyx provides update on Cyprus2+ study, to submit protocol amendment
- Closing Bell Movers: Ultragenyx Pharmaceutical slips 2% on study update